ArticleJournal of cardiothoracic surgery2025
Predictive value of miR-637 for the occurrence of myocardial hypertrophy in patients with hypertension.
Article in Journal of cardiothoracic surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertension is one of the cardiovascular diseases that seriously endangers human life and health, and myocardial hypertrophy is the most common secondary condition of hypertension. Hypertensive with myocardial hypertrophy patients have very high rates of disability and mortality. Previous studies have shown that miR-637 is downregulated in hypertension. Here, our objective was to investigate the correlation and diagnostic potential of serum miR-637 levels in hypertensive patients with myocardial hypertrophy, and to develop new biomarkers for clinical applications.
methodsThe content of serum miR-637 was detected by RT-qPCR. ROC curve was used to analyze the diagnostic accuracy of serum miR-637 in hypertension with myocardial hypertrophy. Logistic analysis was used to evaluate the risk factors associated with hypertension with myocardial hypertrophy. The effect of miR-637 on the viability of H9c2 cells was verified by transfection in vitro. The model of myocardial hypertrophy was established by treating H9c2 cells with Ang II.
resultsCompared with healthy controls, miR-637 expression was attenuated in hypertensive patients and weakest in hypertension patients with myocardial hypertrophy. ROC curve showed high sensitivity (78.8%) and specificity (85.0%) of miR-637 in predicting the occurrence of hypertension with myocardial hypertrophy. miR-637 was a risk factor for predicting the development of hypertension with myocardial hypertrophy and showed a negative correlation with LVMI. Overexpression of miR-637 enhanced H9c2 cell viability and decreased apoptosis rate. Ang II treatment decreased miR-637 expression, inhibited cell proliferation, promoted apoptosis, and increased myocardial hypertrophy markers levels, whereas transfection with miR-637 mimic reversed this trend.
conclusionmiR-637 is poorly expressed in hypertension patients with myocardial hypertrophy and may be an indicator of clinical diagnosis. In addition, miR-637 may serve as a biomarker for diagnosing whether hypertensive patients have myocardial hypertrophy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.